George Lee

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

Cardiva Medical, Inc. designs and develops vascular access management products. It offers VASCADE, an extravascular closure device designed to increase the comfort and safety of vascular closure for patients; and Catalyst, a device that supports the body's natural healing process by enhancing the vessel's inherent natural elastic recoil, tissue apposition and coagulation. The company was founded by Zia Yassinzadeh and Augustine Y. Lien in July 2002 and is headquartered in Santa Clara, CA.

Amkey Ventures LLC (Amkey Ventures) is a venture capital firm founded in 2001 by George J. Lee and Woody Sing-Wood Yeh. The firm headquartered in Fremont, California.

Biokey, Inc. develops and markets generic drugs. Its services include regulatory support, analytical services, product development, and GMP manufacturing. The company was founded by George J. Lee in 2001 and is headquartered in Fremont, CA.

GenePharm, Inc. develops and commercializes therapeutics for skin related problems. Its services include formulation development, pre-clinical research, brand creation. technology licensing, technology alliance, and technology transfer. The company was founded in March 6, 2000 and is headquartered in the Sunnyvale, CA.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

RevMAb Biosciences, Inc. operates as a biotechnology company. It focuses on the development of monoclonal antibodies using a revolutionary technology that does not require cell fusion and hybridoma generation. The company is headquartered in South San Francisco, CA.

Part of Munir Sukhtian Pharmaceuticals, GenePharm Biotech Corp. develops and commercializes preventive and curative therapeutics for skin-related problems. The private company is based in Xizhi District, Taiwan.

Part of Applied BioCode Corp., Applied BioCode, Inc. is a diagnostic testing company that designs, develops, and commercializes multiplex testing products. The private company is based in Santa Fe Springs, CA. Applied BioCode offers a range of diagnostic assays, including the BioCode SARS-CoV-2 assay, the BioCode Respiratory Pathogen Panel, and the BioCode Gastrointestinal Pathogen Panel. The company's technology combines "digital barcodes" with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Beads (BMB) technology. The micro BMBs are about the diameter of a human hair and are the ideal choice for cost-effective high throughput syndromic panels. The company was founded in 2008 by Winston Z. Ho, and Christopher M. Bernard has been the CEO of the company since 2022.

Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation.